Long-term persistence of distinct mutations in genital tract
1 September 2003. Related: Conference reports, Women's health, Drug resistance.
2003
5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Underlying mechanisms: adipocytes and cytokines
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications, Basic science and immunology.
More mitochondrial DNA depletion
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
IMT and cardiovascular risk
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Reduced bone mineral density in HIV-positive women
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Rosiglitazone with insulin resistance
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Additional benefits of exercise with metformin
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Facial fat loss – measuring and treatment
1 September 2003. Related: Conference reports, Treatment access, Lipodystrophy and metabolic complications.
Uridine treatment for mitochondrial toxicity
1 September 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Breast enlargement in men and testosterone treatment
1 September 2003. Related: Conference reports, Lipodystrophy and metabolic complications.
Severe efavirenz psychotic events
1 September 2003. Related: Conference reports, Side effects.
Treatment interruption: a real choice
1 September 2003. Related: Conference reports, Treatment strategies, Lipodystrophy and metabolic complications.
2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris
1 September 2003. Related: Conference reports.
Nevirapine and MTCT: the single-dose backlash
1 September 2003. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, Paediatric care.
Triple nucleoside combinations fail patients again
1 September 2003. Related: Conference reports, Antiretrovirals.
Nucleoside-sparing regimens
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual boosted PIs in salvage therapy
1 September 2003. Related: Conference reports, Antiretrovirals.
BMS reports on atazanavir efficacy and safety in treatment experienced patients
1 September 2003. Related: Conference reports, Antiretrovirals.
Unsupervised treatment interruptions are associated with increased risk of AIDS or death
1 September 2003. Related: Conference reports, Antiretrovirals.
Uridine as a potential treatment for NRTI related mitochondrial toxicity
1 September 2003. Related: Conference reports, PK and drug interactions, Side effects.
Long term exposure to nucleoside analogues and peripheral nerve function
1 September 2003. Related: Conference reports, Side effects.
Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy
1 September 2003. Related: Conference reports, Antiretrovirals, Side effects.
First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age
1 September 2003. Related: Conference reports, Basic science and immunology.
Lessons learned from early HAART in acute HIV infection
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
CD4 cell reconstitution is significantly slower in older patients
1 September 2003. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Pharmacology studies at the 2nd IAS conference
1 September 2003. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Studies highlight problems of rectal disease in HIV-positive patients
1 September 2003. Related: Conference reports, Coinfections and complications.
Appointment of industry executive to supervise US AIDS initiative provokes criticism
1 September 2003. Related: Treatment access.
T-20 launched in UK
1 September 2003. Related: Antiretrovirals.
US guidelines updated (July 2003)
1 September 2003. Related: Guidelines.
US approval of FTC (emtricitabine)
1 September 2003. Related: Antiretrovirals.
Resistance summary of new PIs: atazanavir and tipranavir
1 September 2003. Related: Drug resistance.
Bone mineral metabolism and HIV-infection
1 September 2003. Related: Side effects.
Protease inhibitors and Kaposi’s sarcoma (KS): KS relapse seen after switch from PI to NNRTI
1 September 2003. Related: Coinfections and complications.
UK highest rate of new infections at over 5,000 cases
1 September 2003. Related: Other news.
Medicines Control Agency slated by Commons committee
1 September 2003. Related: Other news.
Conference reports and abstracts
1 September 2003. Related: On the web.
Medscape articles
1 September 2003. Related: On the web.
Newletters and reports
1 September 2003. Related: On the web.
Volume 4 Number 7 August/September 2003 PDF
1 September 2003. Related: PDFs.
Volume 4 Number 6 July 2003
1 July 2003. Related: Editorial.
Activist anger over US ‘ambush’ of the Global Fund
1 July 2003. Related: Treatment access.
$15 billion AIDS bill signed, but full funding shaky
1 July 2003. Related: Treatment access.
New GAA report: US and G8 must act fast to rescue Global Fund
1 July 2003. Related: Treatment access.
World Health Assembly approves resolution supporting public health considerations in drug policy
1 July 2003. Related: Treatment access.
WHO Assembly analysis
1 July 2003. Related: Treatment access.
Bill Gates to give $1 million to Brazil’s AIDS programme
1 July 2003. Related: Treatment access.
Adherence is not a barrier to successful antiretroviral therapy in South Africa
1 July 2003. Related: Treatment access.
T-20 approved in Europe
1 July 2003. Related: Antiretrovirals.
Tenofovir European licence extended to include first-line therapy
1 July 2003. Related: Antiretrovirals.
FDA approves atazanavir in US – a once daily protease inhibitor
1 July 2003. Related: Antiretrovirals.
Atanazavir and saquinavir in salvage therapy: reduced effect on lipids shown in pilot study
1 July 2003. Related: Antiretrovirals.
Major change to OPTIMA salvage therapy study in the UK
1 July 2003. Related: Antiretrovirals.
Is stress associated with CIN progression in HIV-positive women?
1 July 2003. Related: Women's health, Cancer and HIV.
FDA says some follow-up drug studies are never started
1 July 2003. Related: Side effects.
Lamotrigine shows some benefit for HIV-associated painful sensory neuropathies
1 July 2003. Related: Side effects.
HIV and heart disease: D:A:D prevalence rates show importance of accessing CVD risk in HIV patients
1 July 2003. Related: Lipodystrophy and metabolic complications.
HAART increases body fat at first; both d4T and AZT lead to subsequent fat loss
1 July 2003. Related: Lipodystrophy and metabolic complications.
Lipoatrophy improved by switching from d4T to abacavir
1 July 2003. Related: Lipodystrophy and metabolic complications.
T cell activation is associated with decreased CD4+ T cell gains during ARV therapy
1 July 2003. Related: Basic science and immunology.
Structured treatment interruptions trial shows no benefit
1 July 2003. Related: Basic science and immunology.
New antibiotic appears effective against MDR-TB
1 July 2003. Related: TB coinfection.
Tobacco use increases risk for pulmonary diseases and weakens response to therapy in patients on HAART
1 July 2003. Related: Coinfections and complications.